Literature DB >> 23570341

Evaluation of Tyro3 expression, Gas6-mediated Akt phosphorylation, and the impact of anti-Tyro3 antibodies in melanoma cell lines.

Stephen J Demarest1, Jennifer Gardner, Michelle C Vendel, Eric Ailor, Suzanne Szak, Flora Huang, Adam Doern, Xiangyang Tan, Weixing Yang, Dorre A Grueneberg, Edward J Richards, Wilson O Endege, Ed Harlow, Louise A Koopman.   

Abstract

Tyro3, a member of the Tyro3/Axl/Mer (TAM) family of receptor tyrosine kinases, has emerged as a potential oncogene in melanoma. Here, we confirm that Tyro3 is specifically overexpressed in primary melanoma samples and show that Tyro3 is expressed at varying levels in numerous melanoma cell lines. Short hairpin RNA-mediated knockdown of Tyro3 led to significant cell death via apoptotic mechanisms in nearly all melanoma cell lines tested, regardless of the BRAF or NRAS mutation status or co-expression of Axl and/or Mer. We generated soluble and monomeric versions of the human Tyro3 extracellular domain and human Gas6 for affinity measurements and correlated these values with the level of Gas6 required to induce Tyro3 signaling in cellular assays. Calcium was critical for the correct folding of Gas6 and its binding to Tyro3. In melanoma cell lines, Gas6 induced Tyro3 phosphorylation and downstream Akt phosphorylation without apparent effects on Erk. We generated monoclonal antibodies (mAbs) against Tyro3 to examine their effect on survival signaling in melanoma cell lines. The mAbs generated against Tyro3 included nonligand blockers, partial blockers, and competitive ligand blockers. A number of weak and partial ligand blockers (all recognizing the Tyro3 Ig domains) were the most effective at blocking ligand-mediated downstream signaling of Tyro3. Overall, these data indicate that Tyro3 may confer increased survival signals in melanoma cells and can be stymied using inhibitory mAbs. These mAbs may be useful for further investigations of the role of Tyro3 in melanoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23570341     DOI: 10.1021/bi301588c

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  24 in total

Review 1.  Antibodies directed against receptor tyrosine kinases: current and future strategies to fight cancer.

Authors:  Bénédicte Fauvel; Aziz Yasri
Journal:  MAbs       Date:  2014-05-14       Impact factor: 5.857

2.  Kinome profiling of non-Hodgkin lymphoma identifies Tyro3 as a therapeutic target in primary effusion lymphoma.

Authors:  Jason P Wong; Timothy J Stuhlmiller; Louise C Giffin; Carolina Lin; Rachele Bigi; Jichen Zhao; Weihe Zhang; Ariana G Bravo Cruz; Steven I Park; H Shelton Earp; Dirk P Dittmer; Stephen V Frye; Xiaodong Wang; Gary L Johnson; Blossom Damania
Journal:  Proc Natl Acad Sci U S A       Date:  2019-07-25       Impact factor: 11.205

Review 3.  TYRO3: A potential therapeutic target in cancer.

Authors:  Pei-Ling Hsu; Jonathan Jou; Shaw-Jenq Tsai
Journal:  Exp Biol Med (Maywood)       Date:  2019-02-02

Review 4.  The TAM family: phosphatidylserine sensing receptor tyrosine kinases gone awry in cancer.

Authors:  Douglas K Graham; Deborah DeRyckere; Kurtis D Davies; H Shelton Earp
Journal:  Nat Rev Cancer       Date:  2014-12       Impact factor: 60.716

5.  Tyro3 carboxyl terminal region confers stability and contains the autophosphorylation sites.

Authors:  Hanshuang Shao; Douglas Lauffenburger; Alan Wells
Journal:  Biochem Biophys Res Commun       Date:  2017-06-28       Impact factor: 3.575

6.  Tyro3-mediated phosphorylation of ACTN4 at tyrosines is FAK-dependent and decreases susceptibility to cleavage by m-Calpain.

Authors:  Hanshuang Shao; Anna Wang; Douglas Lauffenburger; Alan Wells
Journal:  Int J Biochem Cell Biol       Date:  2017-12-20       Impact factor: 5.085

Review 7.  TAM receptor tyrosine kinases as emerging targets of innate immune checkpoint blockade for cancer therapy.

Authors:  Yemsratch T Akalu; Carla V Rothlin; Sourav Ghosh
Journal:  Immunol Rev       Date:  2017-03       Impact factor: 12.988

8.  Differential TAM receptor-ligand-phospholipid interactions delimit differential TAM bioactivities.

Authors:  Erin D Lew; Jennifer Oh; Patrick G Burrola; Irit Lax; Anna Zagórska; Paqui G Través; Joseph Schlessinger; Greg Lemke
Journal:  Elife       Date:  2014-09-29       Impact factor: 8.140

9.  Mer590, a novel monoclonal antibody targeting MER receptor tyrosine kinase, decreases colony formation and increases chemosensitivity in non-small cell lung cancer.

Authors:  Christopher T Cummings; Rachel M A Linger; Rebecca A Cohen; Susan Sather; Gregory D Kirkpatrick; Kurtis D Davies; Deborah DeRyckere; H Shelton Earp; Douglas K Graham
Journal:  Oncotarget       Date:  2014-11-15

10.  Inhibition of TYRO3/Akt signaling participates in hypoxic injury in hippocampal neurons.

Authors:  Yan-Zhen Zhu; Wei Wang; Na Xian; Bing Wu
Journal:  Neural Regen Res       Date:  2016-05       Impact factor: 5.135

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.